Teresa Puértolas

843 total citations
29 papers, 499 citations indexed

About

Teresa Puértolas is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Teresa Puértolas has authored 29 papers receiving a total of 499 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in Teresa Puértolas's work include Cancer Treatment and Pharmacology (8 papers), Cutaneous Melanoma Detection and Management (8 papers) and Colorectal Cancer Treatments and Studies (7 papers). Teresa Puértolas is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Cutaneous Melanoma Detection and Management (8 papers) and Colorectal Cancer Treatments and Studies (7 papers). Teresa Puértolas collaborates with scholars based in Spain and Switzerland. Teresa Puértolas's co-authors include Á. Artal, Roberto Pazo-Cid, Juan Lao, A. Antón Torres, María Álvarez, Rafael Rosell, María González‐Cao, Niki Karachaliou, Miguel Ángel Molina‐Vila and Ana Drozdowskyj and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Teresa Puértolas

26 papers receiving 491 citations

Peers

Teresa Puértolas
Nicoletta Staropoli Italy
Nancy Paz United States
Austin J. Combest United States
Alex De Caluwé Belgium
Alessandra Bulotta Italy
Yinxing Zhu China
J. Bonneterre France
Songbing Qin China
Justin T. Moyers United States
E. Ruth Plummer United Kingdom
Nicoletta Staropoli Italy
Teresa Puértolas
Citations per year, relative to Teresa Puértolas Teresa Puértolas (= 1×) peers Nicoletta Staropoli

Countries citing papers authored by Teresa Puértolas

Since Specialization
Citations

This map shows the geographic impact of Teresa Puértolas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Teresa Puértolas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Teresa Puértolas more than expected).

Fields of papers citing papers by Teresa Puértolas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Teresa Puértolas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Teresa Puértolas. The network helps show where Teresa Puértolas may publish in the future.

Co-authorship network of co-authors of Teresa Puértolas

This figure shows the co-authorship network connecting the top 25 collaborators of Teresa Puértolas. A scholar is included among the top collaborators of Teresa Puértolas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Teresa Puértolas. Teresa Puértolas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
González‐Cao, María, Teresa Puértolas, José Luís Zamora Manzano, et al.. (2024). Access to melanoma drugs in Spain: a cross-sectional survey. Clinical & Translational Oncology. 26(10). 2572–2583. 3 indexed citations
2.
González‐Cao, María, Teresa Puértolas, José Luís Zamora Manzano, et al.. (2024). Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis. Clinical & Translational Oncology. 27(1). 386–391. 1 indexed citations
3.
Llombart‐Cussac, Antonio, Beatriz Rojas, Raquel Andrés, et al.. (2023). Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study. Cancers. 15(5). 1529–1529. 2 indexed citations
4.
Berciano‐Guerrero, Miguel‐Ángel, Ainara Soria, Guillermo Crespo, et al.. (2023). 1174P Sex differences in advanced melanoma in Spain: Results from the prospective real-world study GEM 1801. Annals of Oncology. 34. S697–S698.
5.
Berciano‐Guerrero, Miguel‐Ángel, Eva Muñoz‐Couselo, José Luís Zamora Manzano, et al.. (2023). Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: Results from the observational study GEM1801.. Journal of Clinical Oncology. 41(16_suppl). 9547–9547.
6.
Piñero, Antonio, Eva Muñoz‐Couselo, José Luís Zamora Manzano, et al.. (2023). 1159P Characterization of melanoma of unknown primary in the era of immunotherapy and targeted therapy in Spain: Results from the prospective real-world study GEM 1801. Annals of Oncology. 34. S691–S692.
7.
Márquez‐Rodas, Iván, Miguel‐Ángel Berciano‐Guerrero, Ainara Soria, et al.. (2022). 848P Second-line systemic treatment for patients with advanced melanoma: Results from the prospective real-world study GEM1801. Annals of Oncology. 33. S937–S938. 1 indexed citations
8.
Izagirre, Neskuts, Conrado Martínez‐Cadenas, Manuel Martín González, et al.. (2022). Association of TYR SNP rs1042602 with Melanoma Risk and Prognosis. Life. 12(12). 2004–2004. 5 indexed citations
9.
González‐Cao, María, José Luís Zamora Manzano, Miguel Ángel Molina‐Vila, et al.. (2018). Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy. Melanoma Research. 28(3). 195–203. 14 indexed citations
10.
Karachaliou, Niki, Guillermo Crespo, Erika Aldeguer, et al.. (2017). Interferon-gamma (INFG), an important marker of response to immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) and melanoma patients.. Journal of Clinical Oncology. 35(15_suppl). 11504–11504. 12 indexed citations
11.
Puértolas, Teresa, et al.. (2016). Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma. Molecular and Clinical Oncology. 5(4). 458–462. 23 indexed citations
12.
García‐Foncillas, Jesús, Pascuala Garcı́a-Martı́nez, Antonio Llombart‐Cussac, et al.. (2012). Dynamic contrast-enhanced MRI versus 18F-misonidazol-PET/CT to predict pathologic response in bevacizumab-based neoadjuvant therapy in breast cancer.. Journal of Clinical Oncology. 30(15_suppl). 10512–10512. 8 indexed citations
13.
López-Vega, José Manuel, Arrate Plazaola, Serafín Morales, et al.. (2012). Activation of angiogenic pathway in the prediction of pathologic response to bevacizumab-based neoadjuvant therapy in breast cancer.. Journal of Clinical Oncology. 30(15_suppl). 10595–10595. 1 indexed citations
14.
Boni, Valentina, José Manuel López-Vega, Pablo Martínez, et al.. (2011). Bevacizumab changes in patients with naïve, stage II-III breast cancer assessed by 18F-fluoromisonidazole and 18F-fluorotymidine PET-CT.. Journal of Clinical Oncology. 29(15_suppl). 2529–2529. 1 indexed citations
15.
Martínez‐Trufero, Javier, Juan Lao, Teresa Puértolas, et al.. (2005). Serum Markers and Prognosis in Locally Advanced Breast Cancer. Tumori Journal. 91(6). 522–530. 15 indexed citations
16.
Puértolas, Teresa, et al.. (2004). Phase II study of vinorelbine (NVB) and UFT in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes. Journal of Clinical Oncology. 22(14_suppl). 751–751. 4 indexed citations
17.
Artal, Á., Javier Martínez‐Trufero, Ana Herrero, et al.. (2003). Increasing-dose gemcitabine plus low-dose cisplatin in metastatic non-small cell lung cancer. Anti-Cancer Drugs. 14(2). 111–118. 2 indexed citations
18.
Maurel, Joan, Teresa Puértolas, Antonio Antón, et al.. (2001). Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Anti-Cancer Drugs. 12(9). 713–717. 20 indexed citations
19.
20.
Artal, Á., et al.. (2000). [Why evidence-based medicine? 20 years of meta-analysis].. PubMed. 17(10). 521–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicoletta Staropoli Breakdown of academic impact, for papers by Nancy Paz Breakdown of academic impact, for papers by Austin J. Combest Breakdown of academic impact, for papers by Alex De Caluwé Breakdown of academic impact, for papers by Alessandra Bulotta Breakdown of academic impact, for papers by Yinxing Zhu Breakdown of academic impact, for papers by J. Bonneterre Breakdown of academic impact, for papers by Songbing Qin Breakdown of academic impact, for papers by Justin T. Moyers Breakdown of academic impact, for papers by E. Ruth Plummer
Rankless by CCL
2026